Navigation Links
NPS Pharmaceuticals Announces Senior Management Changes
Date:2/26/2008

BEDMINSTER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that Dr. Tony Coles will be stepping down from his positions as president, chief executive officer and a director effective March 17, 2008 to become president, chief executive officer and a director of Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX). He will be succeeded by NPS executive vice president and chief operating officer Dr. Francois Nader, who will become president and chief executive officer of NPS.

NPS chairman Peter Tombros stated: "On behalf of the NPS board, I wish Tony much success in his new position and congratulate Francois on his promotion. Francois has been instrumental in developing our new business plan and we are confident that he will lead NPS successfully in the years ahead. He is uniquely well-qualified to guide NPS because of his demonstrated expertise in clinical research and corporate strategy, his many years of pharmaceutical industry experience and his superb management skills. I am confident that he will be a very effective chief executive as the company focuses on executing an ambitious clinical program.

"I also thank Tony for his outstanding service during a challenging period in the company's history. Under his leadership, we shifted our business plan to focus on developing our late-stage products in new specialty indications, raised a significant amount of cash to fund these pipeline investments and consolidated our long-term debt to strengthen the company's balance sheet. We appreciate his lasting contributions to NPS and wish him well in his future endeavors."

Dr. Nader stated: "I appreciate the board's confidence in me to lead NPS and look forward to building upon the vision an
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
2. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
3. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
5. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
6. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
7. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
8. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
9. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
10. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
11. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email: